When Marketing Companies And Call Centers Become Part Of A Substance Abuse Fraud Investigation
Substance abuse treatment providers often rely on outside companies to advertise their services, answer calls from prospective patients, verify insurance information, or connect people with treatment programs. In South Florida’s large treatment and recovery industry, those relationships may involve marketing companies and call centers operating far from the facility itself. A business arrangement intended to generate legitimate inquiries can draw intense scrutiny once investigators begin examining how patients reached a particular provider and how the marketer was paid.
Investigators may look beyond the written contract and reconstruct how the relationship actually operated. Patient admissions, compensation records, call-center activity, communications between the parties, and the way prospective patients were routed may all affect the government’s view of the arrangement. Early legal guidance from a knowledgeable Florida substance abuse treatment fraud lawyer can help distinguish the provider’s role in patient acquisition from conduct controlled by an outside marketing company or call center.
Florida Law Directly Regulates Treatment Marketing and Call Centers
Florida law places specific restrictions on marketing within the substance abuse treatment industry. Florida Statutes § 397.55 applies not only to treatment providers and recovery residences but also to third parties providing advertising or marketing services to them.
The statute prohibits false or misleading marketing and specifically addresses marketers that generate referrals or leads through call centers or web-based platforms. When a marketing provider receives compensation from licensed treatment providers or recovery residences it represents, the law requires disclosures designed to allow prospective patients to understand which facilities are paying the marketer.
A treatment center’s use of an outside marketing company does not by itself establish fraud or patient brokering. Problems may arise when investigators believe the marketer was functioning as a paid referral source rather than providing ordinary advertising or intake services. The details of how leads were generated, presented to prospective patients, and ultimately converted into admissions may shape the investigation.
Compensation Arrangements Often Receive the Closest Scrutiny
How the marketing company was paid may become one of the most heavily examined parts of the relationship. Florida Statutes § 817.505 prohibits offering or receiving commissions, benefits, bonuses, kickbacks, or other remuneration to induce patient referrals to or from health care providers or facilities. The statute also reaches those who aid, abet, advise, or otherwise participate in prohibited patient brokering.
A flat monthly marketing fee may present a different factual picture from compensation that increases with admissions, insured patients, treatment volume, or revenue. Investigators may also examine arrangements labeled as consulting, management, advertising, or lead-generation agreements when payment records suggest that compensation followed the number or value of patients sent to a facility.
Federal law creates another layer of exposure. The Eliminating Kickbacks in Recovery Act, or EKRA, codified at 18 U.S.C. § 220, prohibits certain remuneration connected to referrals to recovery homes, clinical treatment facilities, and laboratories. Its exception for payments to bona fide employees or independent contractors restricts compensation that varies according to factors such as the number of individuals referred or amounts billed to health care benefit programs.
Call Center Records May Reveal More Than the Contract
A written agreement rarely tells investigators exactly what happened when prospective patients called. Call centers may retain recordings, scripts, customer relationship management records, lead-source information, timestamps, insurance verification data, and notes showing where callers were directed. Those records can become central when the government alleges that a marketing company was steering insured patients toward particular treatment facilities.
Call recordings may show whether representatives provided neutral information or pushed callers toward facilities based on insurance coverage, compensation arrangements, or directions from a provider. CRM records may reveal whether the same lead was sold to several facilities or whether certain treatment centers received priority. Communications between call-center managers and facility personnel may also show how closely the businesses coordinated admissions.
The same records may tell a different story from the one investigators initially suspect. A marketer may have controlled its own scripts, advertising campaigns, and lead-routing decisions without the treatment provider directing those operations. Records showing that a facility paid for advertising services rather than individual patients may also change the meaning of communications that appear suspicious when viewed without the surrounding business context.
A Vendor Relationship Can Become the Basis for a Conspiracy Allegation
Federal prosecutors may treat the marketing company and treatment provider as participants in the same alleged scheme rather than as separate businesses. They may contend that marketers, facility owners, employees, or other participants shared an agreement to obtain patients through unlawful referrals and profit from subsequent insurance billing.
Under 18 U.S.C. § 1349, a person who conspires to commit an offense covered by the federal fraud chapter faces the penalties prescribed for the underlying offense. In a substance abuse treatment investigation, communications between marketers and treatment providers may be used to argue that the parties were pursuing a common fraudulent objective.
A commercial relationship alone does not establish what each participant knew or agreed to do. A marketing vendor may serve several facilities, operate its own call center, make independent decisions, and receive information that was never shared with the treatment provider. The distinction between the vendor’s conduct and the facility’s knowledge becomes especially important when investigators try to use ordinary business coordination as evidence of a broader criminal agreement.
Marketing Evidence and Billing Evidence Serve Different Purposes
Patient acquisition frequently becomes intertwined with allegations that treatment services were medically unnecessary, improperly documented, or never provided. Evidence raising questions about a marketing relationship, however, does not automatically establish that subsequent insurance claims were fraudulent.
Federal health care fraud under 18 U.S.C. § 1347 addresses schemes to defraud health care benefit programs or obtain their money through false or fraudulent representations connected with health care services. An investigation may therefore move from the manner in which patients were recruited to the treatment they received, the records supporting that care, and the claims ultimately submitted for payment.
Keeping those factual questions separate matters. A disputed marketing payment does not establish that clinical services were unnecessary, and questionable billing does not prove that an outside marketer participated in creating or submitting the claims. Investigators may attempt to connect both sides of the case into one broader scheme, but the evidence still has to show how particular people or companies were tied to the alleged conduct.
The Full Marketing Relationship Needs to Be Reconstructed
Substance abuse treatment investigations can expand quickly once investigators obtain records from an outside marketer or call center. A provider may suddenly face allegations based on communications or payment data that originated with a third party and are being interpreted without the commercial context in which the relationship operated.
Understanding the arrangement may require tracing who controlled the marketing process, how compensation was calculated, what information passed between the businesses, and whether the provider had any role in decisions later characterized as improper referrals. Advertising records, contracts, payment histories, call-center procedures, and internal communications may show legitimate marketing activity or independent vendor decisions that are difficult to see from a small group of selected messages or transactions.
When investigators are using a third-party marketing relationship to connect a treatment provider to alleged patient brokering or a broader fraud conspiracy, an experienced Florida substance abuse treatment fraud lawyer can place the communications and payment records in the context of how the relationship actually operated.
Contact The Baez Law Firm
If you or your treatment business is under investigation over a marketing company, call center, or patient-referral arrangement, the allegations may reach far beyond the marketing contract itself. Investigators may be examining the vendor relationship as part of a larger theory involving patient brokering, kickbacks, conspiracy, or fraudulent insurance billing.
The Baez Law Firm represents healthcare professionals, treatment providers, business owners, and others facing serious fraud allegations in Miami, throughout Florida, and in federal investigations. Contact The Baez Law Firm to speak with an experienced Florida substance abuse treatment fraud lawyer and learn how we can protect your rights and challenge allegations that a marketing or call-center relationship was part of a broader fraud scheme.
Sources:
- Florida Statutes § 397.55 — Prohibition of Deceptive Marketing Practices
leg.state.fl.us/Statutes/index.cfm?App_mode=Display_Statute&Search_String=&URL=0300-0399%2F0397%2FSections%2F0397.55.html - Florida Statutes § 817.505 — Patient Brokering Prohibited; Exceptions; Penalties
leg.state.fl.us/Statutes/index.cfm?App_mode=Display_Statute&Search_String=&URL=0800-0899%2F0817%2FSections%2F0817.505.html - 18 U.S.C. § 220 — Illegal Remunerations for Referrals to Recovery Homes, Clinical Treatment Facilities, and Laboratories
uscode.house.gov/view.xhtml?edition=2023&num=0&req=granuleid%3AUSC-2023-title18-section220 - 18 U.S.C. § 1347 — Health Care Fraud
uscode.house.gov/view.xhtml?edition=prelim&req=granuleid%3AUSC-prelim-title18-section1347 - 18 U.S.C. § 1349 — Attempt and Conspiracy
uscode.house.gov/view.xhtml?edition=prelim&num=0&req=granuleid%3AUSC-prelim-title18-section1349
